Vascular Biogenics (NASDAQ:VBLT) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, ValuEngine reports.
Several other research analysts also recently issued reports on VBLT. Chardan Capital reiterated a “buy” rating and issued a $3.25 target price on shares of Vascular Biogenics in a research note on Friday, January 10th. Roth Capital reiterated a “buy” rating on shares of Vascular Biogenics in a research note on Thursday, January 2nd. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research note on Friday, November 15th. Finally, Zacks Investment Research upgraded shares of Vascular Biogenics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $2.38.
Shares of NASDAQ VBLT traded up $0.02 during midday trading on Tuesday, hitting $1.41. The stock had a trading volume of 300 shares, compared to its average volume of 111,426. The business’s 50 day moving average is $1.23 and its 200-day moving average is $1.25. The company has a market cap of $50.59 million, a P/E ratio of -2.27 and a beta of -0.29. Vascular Biogenics has a 52 week low of $0.93 and a 52 week high of $1.90. The company has a quick ratio of 5.49, a current ratio of 5.49 and a debt-to-equity ratio of 0.06.
Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Thursday, November 14th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.24 million. Vascular Biogenics had a negative net margin of 3,050.43% and a negative return on equity of 37.19%. As a group, analysts expect that Vascular Biogenics will post -0.52 EPS for the current fiscal year.
A hedge fund recently raised its stake in Vascular Biogenics stock. Morgan Stanley grew its holdings in Vascular Biogenics Ltd (NASDAQ:VBLT) by 6.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 295,012 shares of the biopharmaceutical company’s stock after acquiring an additional 17,900 shares during the period. Morgan Stanley owned 0.82% of Vascular Biogenics worth $383,000 as of its most recent SEC filing. 4.67% of the stock is currently owned by institutional investors and hedge funds.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Recommended Story: Most Active Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.